James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Turner, Megan C., Sabran J. Masoud, Marcelo Cerullo, Mohamed A. Adam, Kevin N. Shah, Dan G. Blazer, James L. Abbruzzese, and Sabino Zani. “Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.” Hpb (Oxford), April 13, 2020. https://doi.org/10.1016/j.hpb.2020.03.006.

PMID
32299656
Full Text

Liu, Joyce F., Su-Chun Cheng, Robert M. Wenham, Andrea E Wahner Hendrickson, Deborah K. Armstrong, Nancy Chan, David E. Cohn, et al. “Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer.” In Clinical Trials. American Association for Cancer Research, 2019. https://doi.org/10.1158/1535-7163.targ-19-a074.

Full Text

Monjazeb, Arta, Anita Giobbie-Hurder, Ana Lako, Mark Awad, Ryan Gentzler, Carrie Lee, Joleen Hubbard, et al. “A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.

Scholars@Duke

Luo, Yongde, Yaying Yang, Muyun Liu, Dan Wang, Feng Wang, Yawei Bi, Juntao Ji, et al. “Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.” Gastroenterology 157, no. 5 (November 2019): 1413-1428.e11. https://doi.org/10.1053/j.gastro.2019.07.030.

PMID
31352001
Full Text

Kent, C. L., D. Marin, D. Niedzwiecki, S. J. Stephens, E. Duffy, M. Malicki, J. Abbruzzese, et al. “Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 105:E238–39. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.06.2014.

Full Text

Xu, Xinyuan, Danwen Qian, Hongliang Liu, Diana Cruz, Sheng Luo, Kyle M. Walsh, James L. Abbruzzese, Xuefeng Zhang, and Qingyi Wei. “Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk.” Mol Carcinog 58, no. 8 (August 2019): 1338–48. https://doi.org/10.1002/mc.23018.

PMID
30997723
Full Text

Yang, Wenjun, Hongliang Liu, Bensong Duan, Xinyuan Xu, Dennis Carmody, Sheng Luo, Kyle M. Walsh, et al. “Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk.” Cancer Sci 110, no. 6 (June 2019): 2022–32. https://doi.org/10.1111/cas.14017.

PMID
30972876
Full Text

Wang, Dan, Yawei Bi, Lianghao Hu, Yongde Luo, Juntao Ji, Albert Z. Mao, Craig D. Logsdon, et al. “Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS.” Cell Commun Signal 17, no. 1 (February 28, 2019): 19. https://doi.org/10.1186/s12964-019-0333-7.

PMID
30819189
Full Text

Luo, Yongde, Dan Wang, James L. Abbruzzese, and Weiqin Lu. “Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells.” Methods Mol Biol 1882 (2019): 207–19. https://doi.org/10.1007/978-1-4939-8879-2_19.

PMID
30378057
Full Text

Stephens, S. J., B. Czito, X. Zhang, E. Duffy, M. Malicki, B. Pitcher, D. Niedzwiecki, et al. “Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S180–S180. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.07.056.

Full Text

Pages